Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 890 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

REVIEW ARTICLE

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future

Kalra Sanjay, Baruah Manash P, Sahay Rakesh K, Unnikrishnan Ambika Gopalakrishnan, Uppal Shweta, Adetunji Omolara

Year : 2016| Volume: 20| Issue : 2 | Page no: 254-267

   This article has been cited by
 
1 GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
Roy Rasalam,John Barlow,Mark Kennedy,Pat Phillips,Alan Wright
Diabetes Therapy. 2019; 10(4): 1205
[Pubmed]  [Google Scholar] [DOI]
2 Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
Sebastian Niezen,Humberto Diaz del Castillo,Lumen A. Mendez Castaner,Alessia Fornoni
Endocrinology, Diabetes & Metabolism. 2019; : e00072
[Pubmed]  [Google Scholar] [DOI]
3 Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Leigh Perreault,Helena Rodbard,Virginia Valentine,Eric Johnson
Advances in Therapy. 2019;
[Pubmed]  [Google Scholar] [DOI]
4 Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
Julio Rosenstock,Christopher H. Sorli,Michael E. Trautmann,Cristóbal Morales,Ulrich Wendisch,George Dailey,Marcus Hompesch,In Young Choi,Jahoon Kang,John Stewart,Kun-Ho Yoon
Diabetes Care. 2019; 42(9): 1733
[Pubmed]  [Google Scholar] [DOI]
5 Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
Sanjay Kalra,Ashok Kumar Das,Rakesh Kumar Sahay,Manash Pratim Baruah,Mangesh Tiwaskar,Sambit Das,Sudip Chatterjee,Banshi Saboo,Ganapathi Bantwal,Saptarshi Bhattacharya,Gagan Priya,Manoj Chawla,Kiraninder Brar,Syed Abbas Raza,Azizul Hasan Aamir,Dina Shrestha,Noel Somasundaram,Prasad Katulanda,Faria Afsana,Shahjada Selim,Mohammad Wali Naseri,Ali Latheef,Manilka Sumanatilleke
Diabetes Therapy. 2019;
[Pubmed]  [Google Scholar] [DOI]
6 Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
Dongzhe Hong,Lei Si,Minghuan Jiang,Hui Shao,Wai-kit Ming,Yingnan Zhao,Yan Li,Lizheng Shi
PharmacoEconomics. 2019;
[Pubmed]  [Google Scholar] [DOI]
7 Narrative review of the effects of antidiabetic drugs on albuminuria
Habib Yaribeygi,Stephen L. Atkin,Niki Katsiki,Amirhossein Sahebkar
Journal of Cellular Physiology. 2018;
[Pubmed]  [Google Scholar] [DOI]
8 GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis
Marco Castellana,Angelo Cignarelli,Francesco Brescia,Luigi Laviola,Francesco Giorgino
Diabetes/Metabolism Research and Reviews. 2018; : e3082
[Pubmed]  [Google Scholar] [DOI]
9 GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
Andrei C. Sposito,Otávio Berwanger,Luiz Sérgio F. de Carvalho,José Francisco Kerr Saraiva
Cardiovascular Diabetology. 2018; 17(1)
[Pubmed]  [Google Scholar] [DOI]
10 Body Weight Considerations in the Management of Type 2 Diabetes
Caroline M. Apovian,Jennifer Okemah,Patrick M. O’Neil
Advances in Therapy. 2018;
[Pubmed]  [Google Scholar] [DOI]
11 A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera,Ana Cebrián-Cuenca,Fernando Álvarez-Guisasola,Fernando Gomez-Peralta,Jesús Reviriego
Diabetes Therapy. 2018;
[Pubmed]  [Google Scholar] [DOI]
12 Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients
Lima Lawrence,Venu Menon,Sangeeta Kashyap
Current Cardiology Reports. 2018; 20(8)
[Pubmed]  [Google Scholar] [DOI]
13 Long-lasting Glucagon-like Peptide 1 Analogue Exendin-4 Ameliorates the Secretory and Synthetic Function of Islets Isolated From Severely Scalded Rats
Dongxu Zhao,Li Ma,Chuanan Shen,Dawei Li,Wenfeng Cheng,Yuru Shang,Zhaoxing Liu,Xin Wang,Kai Yin
Journal of Burn Care & Research. 2018;
[Pubmed]  [Google Scholar] [DOI]
14 A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
Neil Webb,Michelle Orme,Michal Witkowski,Rie Nakanishi,Jakob Langer
Diabetes Therapy. 2018;
[Pubmed]  [Google Scholar] [DOI]
15 The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease
Carlota Recio,Francesco Maione,Asif J. Iqbal,Nicola Mascolo,Vincenzo De Feo
Frontiers in Pharmacology. 2017; 7
[Pubmed]  [Google Scholar] [DOI]
16 Emerging technologies to achieve oral delivery of GLP-1 and GLP-1 analogs for treatment of type 2 diabetes mellitus (T2DM)
Shengwu Ma,Liang We,Hongji Yang,Shaoping Deng,Anthony M. Jevnikar
Canadian Journal of Biotechnology. 2017; 1(1): 1
[Pubmed]  [Google Scholar] [DOI]
17 Lixisenatide: A New Option for Managing Type 2 Diabetes
Jonathan S. Newsome
Journal of Pharmacy Technology. 2017; 33(5): 195
[Pubmed]  [Google Scholar] [DOI]
18 The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
Jerry Meece
Advances in Therapy. 2017;
[Pubmed]  [Google Scholar] [DOI]
19 Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
Ying Liu,Xia Jiang,Xin Chen
Lipids in Health and Disease. 2017; 16(1)
[Pubmed]  [Google Scholar] [DOI]
20 The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
Anne Řrgaard,Jens J. Holst
Diabetologia. 2017;
[Pubmed]  [Google Scholar] [DOI]
21 Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long-term efficacy with or without rescue therapy
Philip D. Home,Bo Ahrén,Jane E.B. Reusch,Marc Rendell,Peter N. Weissman,Deborah T. Cirkel,Diane Miller,Philip Ambery,Molly C. Carr,Michael A. Nauck
Diabetes Research and Clinical Practice. 2017;
[Pubmed]  [Google Scholar] [DOI]
22 Selective beneficial cardiometabolic effects of vertical sleeve gastrectomy are predominantly mediated through glucagon-like peptide (GLP-1) in Zucker diabetic fatty rats
Sunil Kumar,Raymond Lau,Thomas Palaia,Christopher Hall,Jenny Lee,Keneth Hall,Collin E. Brathwaite,Louis Ragolia
Annals of Medicine and Surgery. 2016; 12: 65
[Pubmed]  [Google Scholar] [DOI]

 

Read this article